Breaking News Instant updates and real-time market news.

GM

General Motors

$32.53

-0.15 (-0.46%)

, GILD

Gilead

$76.21

-1.36 (-1.75%)

04:55
10/07/16
10/07
04:55
10/07/16
04:55

Salesforce to hold an expo

Dreamforce Expo 2016 is being held in San Francisco on October 4-7.

GM

General Motors

$32.53

-0.15 (-0.46%)

GILD

Gilead

$76.21

-1.36 (-1.75%)

FORR

Forrester

$38.50

-0.05 (-0.13%)

SBGSY

Schneider Electric

$14.06

0.212 (1.53%)

SPLK

Splunk

$60.20

-0.69 (-1.13%)

CRM

Salesforce

$71.26

2.84 (4.15%)

  • 23

    Oct

  • 25

    Oct

  • 06

    Nov

  • 11

    Nov

GM General Motors
$32.53

-0.15 (-0.46%)

10/06/16
GSCO
10/06/16
NO CHANGE
GSCO
Autos and Autos Parts sector downgraded to Cautious from Neutral at Goldman
Goldman analyst David Tamberrino downgraded the Autos and Auto Parts sector to Cautious from Neutral saying the US Auto cycle peaked in 2015 and is being held up by increasing OEM incentives. The analyst said OEM earnings will decline in 2017/2018 as negative pricing and lower production pressure North American results, but expects suppliers' earnings to hold up longer. The analyst sees upside to Delphi (DLPH) and Harman (HAR) given exposure to secular growth areas and upside to Goodyear Tire (GT) given secular HVA tire growth. Tamberrino downgraded Lear (LEA) to Sell citing elevated expectations and valuation, cut BorgWarner (BWA) to Neutral on valuation, downgraded Tesla (TSLA) to Neutral on execution risk and capital deployment, and upgraded AutoNation (AN) to Neutral given a more defensive business.
09/20/16
NOMU
09/20/16
INITIATION
Target $33
NOMU
Neutral
General Motors initiated with a Neutral at Nomura
Nomura analyst Anindya Das initiated General Motors with a Neutral and a $33 price target. The analyst said General Motors has significant exposure to the Chinese auto market and is concerned about pricing pressures in the market. Further, the company has yet to break even in Europe on an annual basis and its near-term prospects are clouded by Brexit uncertainties.
09/19/16
09/19/16
UPGRADE
Target $37

Overweight
General Motors upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley upgraded General Motors to Overweight from Equal Weight and increased its price target to $37 from $29. Analyst Adam Jonas raised near-term earnings estimates 5% above consensus and believes even flat earnings in 2017 and 2018 would be received as a positive surprise by the market. Further, the analyst said investors are underestimating how long the auto cycle can last and that General Motor's earnings and free cash flow could have a materially longer duration than the market is currently discounting. He believes investors are overlooking the time and steps needed for fully autonomous transport and said management has a healthy and realistic acceptance that it can't and should not do everything alone and will likely explore new business structures with the potential of positive values.
09/19/16
09/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he believes even flat earnings in 2017 and 2018 would be received as a positive surprise by the market. 2. Wells Fargo (WFC) upgraded to Outperform from Neutral at Baird analyst David George saying he believes the recent pullback is a buying opportunity. 3. Lockheed Martin (LMT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Sam Pearlstein saying he believes the company's earnings can grow 20% per year through 2020. 4. U.S. Steel (X), AK Steel (AKS), and Olympic Steel (ZEUS) were upgraded to Sector Weight from Underweight at KeyBanc with analyst Ivan Marcuse saying the stocks at current levels better reflect the more competitive market conditions he expects in Q4 and 2017. 5. Mattel (MAT) upgraded to Buy from Neutral at Monness Crespi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$76.21

-1.36 (-1.75%)

09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
FORR Forrester
$38.50

-0.05 (-0.13%)

SBGSY Schneider Electric
$14.06

0.212 (1.53%)

SPLK Splunk
$60.20

-0.69 (-1.13%)

08/26/16
NEED
08/26/16
NO CHANGE
NEED
Hold
Needham not seeing catalyst for upside to Splunk shares
Needham analyst Scott Zeller notes that Splunk's Q2 results were another "beat and raise" and says he is impressed with the growth the company is seeing in its Splunk Cloud offering. However, the analyst struggles to see an upside catalyst to shares, with decelerating revenues and billings. Zeller reiterates a Hold rating on the stock.
08/26/16
MSCO
08/26/16
NO CHANGE
MSCO
Splunk fundamentals reamin intact, says Morgan Stanley
10/04/16
GUGG
10/04/16
DOWNGRADE
GUGG
Neutral
Splunk downgraded to Neutral from Buy at Guggenheim
09/21/16
MZHO
09/21/16
INITIATION
Target $60
MZHO
Neutral
Splunk initiated with a Neutral at Mizuho
Mizuho initiated Splunk with a Neutral and a $60 price target.
CRM Salesforce
$71.26

2.84 (4.15%)

10/06/16
ROTH
10/06/16
NO CHANGE
Target $103
ROTH
Buy
Salesforce should be bought on pullback, says Roth Capital
Roth Capital analyst Richard Baldry says Salesforce's (CRM) shares are down roughly 20% from their recent highs, pressured by rumors of a potential bid for Twitter (TWTR) and a recent revenue guidance increase for the second half of 2017 that was back-end loaded enough to leave his Q3 forecast lowered. However, the analyst believes the pullback offers investors an attractive entry point and advocates buying on weakness. Baldry reiterates a Buy rating and $103 price target on Salesforce's shares given the company's strong fundamentals and sector dominance.
10/06/16
BARD
10/06/16
NO CHANGE
Target $90
BARD
Outperform
Salesforce shares should be bought, says Baird
Baird analyst Steven Ashley noted that Salesforce (CRM) CEO Mark Benioff said his company has all the customer data it needs, which he reads as meaning it would not need to make an acquisition of Twitter (TWTR) purely for data. The analyst also said the company's board is acutely aware of their responsibility to shareholders when it comes to Salesforce's stock and the potential negative impact on shares that a Twitter deal could pose. Ashley reiterated his Outperform rating and $90 price target on Salesforce shares.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Salesforce shares should rebound with no Twitter deal, says Cowen
Cowen analyst J.Derrick Wood expects shares of Salesforce (CRM) to rebound if the company does not buy Twitter (TWTR), which he believes will not happen. The analyst believes investors will return to fundamentals and the analyst believes upside momentum in Salesforce's core business will return in Q3. Wood reiterated his Outperform rating and $100 price target on Salesforce shares.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.

TODAY'S FREE FLY STORIES

PSTG

Pure Storage

$12.16

-0.17 (-1.38%)

14:12
12/09/16
12/09
14:12
12/09/16
14:12
Conference/Events
Pure Storage participates in a conference call with Stifel »

Stifel's Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

IX

ORIX Corp

$82.04

0.99 (1.22%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Upgrade
ORIX Corp rating change  »

ORIX Corp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$15.43

0.585 (3.94%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Options
Transocean short-term puts active as shares see strength »

Transocean short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NMR

Nomura

$6.70

0.22 (3.40%)

14:08
12/09/16
12/09
14:08
12/09/16
14:08
Upgrade
Nomura rating change  »

Nomura upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$57.13

-0.06 (-0.10%)

14:06
12/09/16
12/09
14:06
12/09/16
14:06
Downgrade
MetLife rating change  »

MetLife downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

14:05
12/09/16
12/09
14:05
12/09/16
14:05
General news
Treasury Action: next week's auctions could be difficult »

Treasury Action: next…

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

14:00
12/09/16
12/09
14:00
12/09/16
14:00
Options
Bullish yearend play in the PowerShares QQQ ETF »

Bullish yearend play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
12/09/16
12/09
13:50
12/09/16
13:50
General news
Action Economics Survey results: equities continue to charge ahead »

Action Economics Survey…

CFX

Colfax

$39.04

-0.245 (-0.62%)

13:49
12/09/16
12/09
13:49
12/09/16
13:49
Conference/Events
Colfax to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

13:45
12/09/16
12/09
13:45
12/09/16
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY moved…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

, NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Hot Stocks
Bow Street confirms $13 per share offer for Northstar Realty Europe Corp. »

Bow Street, which holds a…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CALA

Calithera Biosciences

$3.20

-0.05 (-1.54%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Conference/Events
Calithera Biosciences to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BAC

Bank of America

$23.03

0.075 (0.33%)

13:40
12/09/16
12/09
13:40
12/09/16
13:40
Options
Eight year highs and flat skew draw ratio call spreader in Bank of America »

Eight year highs and flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

VIA

Viacom

$42.60

0.45 (1.07%)

, VIAB

Viacom

$38.80

0.79 (2.08%)

13:37
12/09/16
12/09
13:37
12/09/16
13:37
Hot Stocks
Box Office Battle: 'Office Christmas Party' looks to topple 'Moana' »

Opening this weekend, and…

VIA

Viacom

$42.60

0.45 (1.07%)

VIAB

Viacom

$38.80

0.79 (2.08%)

CMCSK

Comcast

CMCSA

Comcast

$69.23

-0.1 (-0.14%)

SNE

Sony

$29.40

0.24 (0.82%)

FOXA

21st Century Fox

$28.64

0.53 (1.89%)

FOX

21st Century Fox

$28.48

0.53 (1.90%)

DIS

Disney

$103.84

0.46 (0.44%)

TWX

Time Warner

$94.89

0.34 (0.36%)

LGF

Lionsgate

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHC

VirnetX

$2.95

-0.35 (-10.61%)

, AAPL

Apple

$112.12

1.09 (0.98%)

13:32
12/09/16
12/09
13:32
12/09/16
13:32
Hot Stocks
VirnetX says U.S. Federal Circuit Appeals Court issued three appeal decisions »

VirnetX announced that on…

VHC

VirnetX

$2.95

-0.35 (-10.61%)

AAPL

Apple

$112.12

1.09 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

AFL

Aflac

$68.79

-0.83 (-1.19%)

13:25
12/09/16
12/09
13:25
12/09/16
13:25
Options
AFLAC call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
12/09/16
12/09
13:25
12/09/16
13:25
General news
Energy Action: Weekly Baker-Hughes rig count »

Energy Action: Weekly…

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:20
12/09/16
12/09
13:20
12/09/16
13:20
Downgrade
TETRA rating change  »

TETRA downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

$NYE

NYSE Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NASDAQ market internals summary »

Volume is extremely heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

, XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

13:13
12/09/16
12/09
13:13
12/09/16
13:13
Technical Analysis
On The Fly: ETF fund flow highlights »

The week saw very large…

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

XLP

Consumer Staples Sector SPDR

$51.86

0.56 (1.09%)

XLI

Industrial Select Sector SPDR

$63.87

0.18 (0.28%)

VOO

Vanguard S&P 500 ETF

$207.39

0.65 (0.31%)

JNK

SPDR Barclays High Yield Bond

$36.47

0.0085 (0.02%)

IEMG

iShares Core MSCI Emerging Markets

$43.94

-0.165 (-0.37%)

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

USO

United States Oil Fund

$11.42

0.11 (0.97%)

XOP

SPDR Oil Exploration and Production Fund

$43.19

-0.16 (-0.37%)

UWTI

VelocityShares 3x Long Crude Oil ETN

IBB

iShares Nasdaq Biotechnology Index

$268.52

2.24 (0.84%)

GLD

SPDR Gold Trust

$110.63

-0.94 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:12
12/09/16
12/09
13:12
12/09/16
13:12
Downgrade
TETRA rating change  »

TETRA downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

IRM

Iron Mountain

$34.71

-0.28 (-0.80%)

13:11
12/09/16
12/09
13:11
12/09/16
13:11
Hot Stocks
Iron Mountain receives approval to sell C21 to Oasis Group »

Iron Mountain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

13:10
12/09/16
12/09
13:10
12/09/16
13:10
Hot Stocks
Biogen off highs after disclosing serious adverse event in Alzheimer's trial »

Shares of Biogen are well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$29.28

0.63 (2.20%)

13:10
12/09/16
12/09
13:10
12/09/16
13:10
Options
MGM calls active as shares move off session highs »

MGM calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.